A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Advanced Solid Tumor
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.4
5 insiders sold shares within a month
Since May 21, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 499 (planned)
- Started
- Jul 29, 2026
- Main results expected
- Mar 31, 2031
- Fully finished
- Mar 31, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A1: Number of Dose-Limiting Toxicities (DLTs) of ARV-6723
Measured over: 21 days from first ARV-6723 administration
Part A1: Number of Participants With Adverse Events (AEs)
Measured over: From the first dose of ARV-6723 through at least 28 days after the last dose (up to approximately 4.7 years)
Part A2: Number of Participants With AEs
Measured over: From the first dose of ARV-6723 through at least 28 days after the last dose (up to approximately 4.7 years)
Part A2: Overall Response Rate (ORR) by computed tomography/magnetic resonance imaging (CT/MRI) Using Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) Criteria Per Investigator Assessment
Measured over: Approximately 24 months
Part B: ORR by CT/MRI using RECIST v1.1 Criteria Per Investigator Assessment
Measured over: Approximately 24 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.4, since 2026-05-21, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07749586 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC